IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.”
POTOMAC, MD / ACCESS Newswire / December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a...
